← Back to caseVisit packet · Tim Foster · Generated Mar 2, 2026
ScoutMyCase.com
Visit summary · in plain words
Tim Foster
Visit of Mar 2, 2026
With Dr. Hale
Start here
Here's what we found, in plain words.
The pages after this one are written for Tim's doctor — they're detailed and technical on purpose. This page is for you. It says the same thing, simply.
The situation
Tim was just diagnosed with glioblastoma, a brain tumor, and had surgery to remove it on February 17. The question now is what treatment comes next — and his tumor has a specific genetic change that opens a targeted option.
The one option worth raising
There's a trial at Northwestern in Chicago, about a three-hour drive, built for tumors with the exact change found in Tim's (an MTAP deletion). The catch: he can only join before radiation begins — about a week away. His own hospital doesn't run it, which is the main reason it could be missed.
What to ask on Tuesday
Just one thing to start: "Could this trial at Northwestern (NCT06556563) be right for Tim — and can we refer before radiation starts?" The detailed pages have everything Dr. Hale needs to answer, plus two backup options.
You don't need to read the technical pages. Hand them to the doctor — they're there if the conversation goes deeper.
Three options worth discussing — one with a closing window.
A short list compiled from Tim's surgery, pathology, and Caris molecular reports. Each match screened against current eligibility. Two facts to confirm, three questions to bring — and one trial that closes once radiation starts.
Patient
Tim Foster, 51
Diagnosis
Glioblastoma, IDH-wildtype, frontal lobe
Key markers
MTAP / CDKN2A deleted · MGMT unmethylated
Surgery
Resection · Feb 17, 2026
The match worth bringing in first.
A trial your team's hospital doesn't run — but referrable to Northwestern, if it happens before radiation.
Match #1 · Strong fit
A phase 1/2 trial of a PRMT5 inhibitor for MTAP-deleted, newly diagnosed glioblastoma.
Accepting
Identifier
NCT06556563
Site
Northwestern Medicine, Chicago · 185 mi
Principal investigator
Dr. A. Vance, MD
Coordinator
Neuro-onc trials · (312) 555-0142
Why this one fits him.
Each criterion in the trial protocol checked against Tim's records. Sourced and dated.
✓
Histology — glioblastoma, IDH-wildtype
IU Health pathology, Feb 19, 2026
✓
MTAP / CDKN2A homozygous deletion
Caris MI Cancer Seek, Mar 1, 2026
✓
Newly diagnosed, post-resection
Craniotomy + resection, Feb 17, 2026
✓
Age 18–75
DOB on file · age 51
✓
KPS ≥ 70 · adequate organ function
KPS 80 (confirm) · pre-op labs in range
!
Must enroll before chemoradiation — closes in ~1 week
Eligibility ends once radiation begins. Radiation planning is underway.
Page 1 of 2 · SMC-2026-03307Prepared by ScoutMyCase · scoutmycase.com
ScoutMyCase.com
Visit packet · continued
Tim Foster
Case SMC-2026-03307
Before radiation begins
Three questions to bring Tuesday.
Specific, decision-moving. Not the usual "what should I ask my doctor."
01
Can we refer to the Northwestern trial (NCT06556563) before radiation starts? The window is about a week.
Eligibility for this MTAP-deletion trial closes once chemoradiation begins. A referral this week is what keeps the option open.
02
Given MGMT is unmethylated, how much benefit do you expect from temozolomide alone?
Unmethylated MGMT predicts reduced benefit from the standard chemo — which is part of why a targeted trial is worth weighing now rather than later.
03
Can we confirm KPS and steroid dose, and order germline HLA typing in case the vaccine trial is an option?
KPS and steroid dose are estimates the trial needs documented. HLA typing (now predicted from tumor) takes time — ordering it in parallel keeps the vaccine trial open.
Two facts to confirm at intake
Performance status & steroid dose
Recorded as KPS 80 / ECOG 1 and dexamethasone 2 mg — noted as estimates. The trial needs them confirmed.
Radiation start date
This is the clock on Match #1 — eligibility ends once chemoradiation begins, about a week out. Confirm the planned date.
If Match #1 doesn't pan out
Standard of care — Radiation + temozolomide ± tumor-treating fields · Indiana University Health (current site). Available now; MGMT unmethylated means lower chemo benefit.
Match #3 — NCT04116658 · Personalized neoantigen vaccine · Mayo Clinic. Needs confirmed germline HLA typing.
Records reviewed
46 documents indexed and cross-referenced. The most relevant:
Mar 1 · 2026
Caris MI Cancer Seek — MTAP/CDKN2A deletion, MGMT unmethylated